Evolus Inc EOLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
-
Evolus to Participate in The Jefferies Global Healthcare Conference
-
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
-
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
-
Evolus to Report First Quarter Financial Results on May 4, 2026
-
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $6.63
- Day Range
- $6.67–7.00
- 52-Week Range
- $3.86–10.20
- Bid/Ask
- $6.51 / $6.94
- Shares Outstanding
- 65.85M
- Market Cap
- $443.86M
- Volume/Avg
- 17 / 862,292
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.45
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 350
- Website
- https://www.evolus.com
Valuation
|
Metric
|
EOLS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.45 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EOLS
|
|---|---|
Quick Ratio | 1.50 |
Current Ratio | 2.04 |
Interest Coverage | −1.29 |
Quick Ratio
EOLS
Profitability
|
Metric
|
EOLS
|
|---|---|
Return on Assets (Normalized) | −12.00% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −9.60% |
Return on Assets
EOLS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| ARYx Therapeutics Inc
ARYX
| — | Ccjqs | — | |||
| Merck KGaA
MKGAF
| — | Cvrgj | $67B | |||
| Merck KGaA ADR
MKKGY
| Drlnhwmb | Dpnqhtf | $67B | |||
| Galderma Group AG ADR
GALDY
| — | Vfdvtr | $51B | |||
| Galderma Group AG Registered Shares
GDERF
| — | Mknqd | $51B | |||
| Takeda Pharmaceutical Co Ltd
TKPHF
| — | Brmw | $49B | |||
| Takeda Pharmaceutical Co Ltd ADR
TAK
| — | Clwn | $49B | |||
| Jiangsu Hengrui Pharmaceuticals Co Ltd ADR
JHPCY
| — | Vtwlgvc | $47B | |||
| Haleon PLC ADR
HLN
| Lbtgplll | Ntvf | $40B | |||
| Haleon PLC
HLNCF
| — | Vdr | $40B |
United States